Search

Your search keyword '"Antonelli G."' showing total 1,294 results
Start Over Author "Antonelli G." Language english
1,294 results on '"Antonelli G."'

1. Antibiotic Resistance and Therapy Outcome in H. pylori Eradication Failure Patients

Author

Saracino I.M., Pavoni M., Zullo A., Fiorini G., Saccomanno L., Lazzarotto T., Cavallo R., Antonelli G., and Vaira D.

Subjects
h. pylori, non-naïve patients, antibiotic resistance, antibiotic susceptibility test, rescue therapies, Therapeutics. Pharmacology, RM1-950
Abstract

Helicobacter pylori (H. pylori) eradication fails in a definite amount of patients despite one or more therapeutic attempts. Curing these patients is progressively more difficult, due to development of antibiotic resistance. Current guidelines suggest testing antibiotic susceptibility in H. pylori isolates following two therapeutic attempts. Aim: to evaluate the development of antibiotic resistance, MIC values trends and therapeutic outcomes in patients who failed at least one H. pylori eradication therapy. Methods: consecutive patients, referred to perform upper gastrointestinal endoscopy (UGIE) to our Unit from January 2009 to January 2019 following at least one therapeutic attempt were considered. Bacterial resistance towards clarithromycin, metronidazole and levofloxacin was tested. Patients received either a susceptibility-guided therapy or Pylera®. Results: a total of 1223 patients were H. pylori positive, and antibiotic susceptibility was available for 1037. The rate of antibiotic resistance and MIC values significantly increased paralleling the number of previous therapeutic attempts. Eradication rates of antibiogram-tailored therapies remained stable, except for the sequential therapy if used as a third line. As a rescue treatment, the Pylera® therapy achieved cure rates comparable to those of the other culture-guided therapies. Conclusions: A significant increase in the secondary resistance towards the three tested antibiotics was observed, both as rate and MIC values, in correlation with the number of therapy failures. These findings should be considered when administering an empirical second-line therapy. Pylera® therapy eradication rates are comparable to culture-tailored therapies.

Published
2020
Full Text
View/download PDF

11. 3-D NAND Oxide/Nitride Tier Stack Thickness and Zonal Measurements With Infrared Metrology.

Author

Wang, Youcheng, Chen, Zhuo, Wang, Cong, Keller, Nick, Andrew Antonelli, G., Liu, Zhuan, Ribaudo, Troy, and Grynko, Rostislav

Subjects
MACHINE learning, SILICON compounds, THICKNESS measurement, SEMICONDUCTOR devices, NITRIDES
Abstract

Three dimensional Not-And (3D NAND) flash memory devices are scaling in the vertical direction to more than 200 oxide/sacrificial wordline nitride layers to further increase storage capacity and enhance energy efficiency. The accurate measurement of the thicknesses of these layers is critical to controlling stress-induced wafer warping and pattern distortion. While traditional optical metrology in the UV-vis-NIR range offers a non-destructive inline solution for high volume manufacturing, we demonstrate in this paper, that mid-IR metrology has advantages in de-correlating oxide and nitride thicknesses owing to their unique absorption signatures. Furthermore, because of the depths sensitivity of oxide and nitride absorptions, the simulated measurement results show the ability to differentiate thickness variations in the vertical zones. Good blind test results were obtained with a machine learning model trained on pseudo-references and pseudo spectra with added skew. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper

Author

Sarmati, L., Andreoni, M., Antonelli, G., Arcese, W., Bruno, R., Coppola, N., Gaeta, G.B., Galli, M., Girmenia, C., Mikulska, M., Pane, F., Perno, C.F., Picardi, M., Puoti, M., Rambaldi, A., Svicher, V., Taliani, G., and Gentile, G.

Published
2017
Full Text
View/download PDF

21. Bevacizumab in the treatment of NSCLC: patient selection and perspectives

Author

Russo AE, Priolo D, Antonelli G, Libra M, Mccubrey JA, and Ferraù F

Subjects
bevacizumab, non-squamous NSCLC, eligibility, safety, subpopulations, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Alessia E Russo,1 Domenico Priolo,1 Giovanna Antonelli,1 Massimo Libra,2 James A McCubrey,3 Francesco Ferraù1 1Medical Oncology Department, San Vincenzo Hospital, Taormina (Messina), Italy; 2Laboratory of Translational Oncology & Functional Genomics, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy; 3Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA Abstract: Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers, and more than half of NSCLCs are diagnosed at an advanced stage. Chemotherapy has reached a plateau in the overall survival curve of about 10 months. Therefore, in last decade novel targeted approaches have been developed to extend survival of these patients, including antiangiogenic treatment. Vascular endothelial growth factor (VEGF) signaling pathway plays a dominant role in stimulating angiogenesis, which is the main process promoting tumor growth and metastasis. Bevacizumab (bev; Avastin®) is a recombinant humanized monoclonal antibody that neutralizes VEGF’s biologic activity through a steric blocking of its binding with VEGF receptor. Currently, bev is the only antiangiogenic agent approved for the first-line treatment of advanced or recurrent nonsquamous NSCLC in “bev-eligible” patients. The ineligibility to receive bev is related to its toxicity. In the pivotal trials of bev in NSCLC, fatal bleeding events including pulmonary hemorrhage were observed with rates higher in the chemotherapy-plus-bev group. Therefore, in order to reduce the incidence of severe pulmonary hemorrhage, numerous exclusion criteria have been characteristically applied for bev such as central tumor localization or tumor cavitation, use of anticoagulant therapy, presence of brain metastases, age of patients (elderly). Subsequent studies designed to evaluate the safety of bev have demonstrated that this agent is safe and well tolerated even in those patients subpopulations excluded from pivotal trials. This review outlines the current state-of-the-art on bev use in advanced NSCLC. It also describes patient selection and future perspectives on this antiangiogenic agent. Keywords: bevacizumab, nonsquamous NSCLC, eligibility, safety, subpopulations

Published
2017

30. Experimental evidence of effective human–AI collaboration in medical decision-making

Author

Reverberi C., Rigon T., Solari A., Hassan C., Cherubini P., Antonelli G., Awadie H., Bernhofer S., Carballal S., Dinis-Ribeiro M., Fernandez-Clotett A., Esparrach G. F., Gralnek I., Higasa Y., Hirabayashi T., Hirai T., Iwatate M., Kawano M., Mader M., Maieron A., Mattes S., Nakai T., Ordas I., Ortigao R., Zuniga O. O., Pellise M., Pinto C., Riedl F., Sanchez A., Steiner E., Tanaka Y., Cherubini A., Reverberi, C, Rigon, T, Solari, A, Hassan, C, Cherubini, P, Antonelli, G, Awadie, H, Bernhofer, S, Carballal, S, Dinis-Ribeiro, M, Fernandez-Clotett, A, Esparrach, G, Gralnek, I, Higasa, Y, Hirabayashi, T, Hirai, T, Iwatate, M, Kawano, M, Mader, M, Maieron, A, Mattes, S, Nakai, T, Ordas, I, Ortigao, R, Zuniga, O, Pellise, M, Pinto, C, Riedl, F, Sanchez, A, Steiner, E, Tanaka, Y, and Cherubini, A

Subjects
Multidisciplinary, Artificial Intelligence, Clinical Decision-Making, Humans, Bayes Theorem, M-PSI/01 - PSICOLOGIA GENERALE, Human
Abstract

Artificial Intelligence (ai) systems are precious support for decision-making, with many applications also in the medical domain. The interaction betweenmds andaienjoys a renewed interest following the increased possibilities of deep learning devices. However, we still have limited evidence-based knowledge of the context, design, and psychological mechanisms that craft an optimal human–aicollaboration. In this multicentric study, 21 endoscopists reviewed 504 videos of lesions prospectively acquired from real colonoscopies. They were asked to provide an optical diagnosis with and without the assistance of anaisupport system. Endoscopists were influenced byai($$\textsc {or}=3.05$$OR=3.05), but not erratically: they followed theaiadvice more when it was correct ($$\textsc {or}=3.48$$OR=3.48) than incorrect ($$\textsc {or}=1.85$$OR=1.85). Endoscopists achieved this outcome through a weighted integration of their and theaiopinions, considering the case-by-case estimations of the two reliabilities. This Bayesian-like rational behavior allowed the human–aihybrid team to outperform both agents taken alone. We discuss the features of the human–aiinteraction that determined this favorable outcome.

Published
2022

38. Impact of the COVID-19 pandemic on surgery for thyroid cancer in Italy: nationwide retrospective study

Author

Medas, F., Ansaldo, G. L., Avenia, N., Basili, G., Bononi, M., Bove, A., Carcoforo, P., Casaril, A., Cavallaro, G., Conzo, G., De Pasquale, L., Del Rio, P., Dionigi, G., Dobrinja, C., Docimo, G., Graceffa, G., Iacobone, M., Innaro, N., Lombardi, C. P., Novelli, G., Palestini, N., Pedicini, F., Perigli, G., Pezzolla, A., Pezzullo, L., Scerrino, G., Spiezia, S., Testini, M., Calo, P. G., Anedda, G., Antonelli, G., Arrigoni, G., Badii, B., Bonati, E., Boniardi, M., Bulfamante, A. M., Candalise, V., Cangiano, A., Canu, G. L., Cappellacci, F., Caracciolo, A., Caruso, E., Casal Ide, E., Chiappini, A., Chiofalo, M. G., Cipolla, C., Costigliola, L., Cozzani, F., Crocco, A., Crocetti, D., De Manzini, N., DI Gioia, A., DI Resta, V., Eramo, R., Erdas, E., Ferriolo, S., Filardo, M., Filograna Pignatelli, M., Gervasi, R., Giudici, F., Gordini, L., Gurrado, A., Impellizzeri, H., Inama, M., Koleva Radica, M., Laforgia, R., Lattarulo, S., Loderer, T., Lucchini, R., Mascioli, F., Marcellinaro, R., Menditto, R., Melfa, G., Minuto, M., Misso, C., Offi, C., Orlando, G., Ossola, P., Pagetta, C., Pasculli, A., Patrone, R., Pauna, I., Pennetti Pennella, F., Pietrasanta, D., Pino, A., Pinto, V. L., Piras, S., Polistena, A., Portinari, M., Reina, S., Rotolo, G., Russo, G., Scalise, E., Sgaramella, L. I., Sibilla, M. G., Spinelli, S., Spoletini, D., Curto, L. S., Tascone, M., Torresan, F., Varaldo, E., Viviani, E., Zucca, A., Medas, F, Ansaldo, G L, Avenia, N, Basili, G, Bononi, M, Bove, A, Carcoforo, P, Casaril, A, Cavallaro, G, Conzo, G, De Pasquale, L, Del Rio, P, Dionigi, G, Dobrinja, C, Docimo, G, Graceffa, G, Iacobone, M, Innaro, N, Lombardi, C P, Novelli, G, Palestini, N, Pedicini, F, Perigli, G, Pezzolla, A, Pezzullo, L, Scerrino, G, Spiezia, S, Testini, M, Calò, P G, Cipolla C, Medas, F., Ansaldo, G. L., Avenia, N., Basili, G., Bononi, M., Bove, A., Carcoforo, P., Casaril, A., Cavallaro, G., Conzo, G., De Pasquale, L., Del Rio, P., Dionigi, G., Dobrinja, C., Docimo, G., Graceffa, G., Iacobone, M., Innaro, N., Lombardi, C. P., Novelli, G., Palestini, N., Pedicini, F., Perigli, G., Pezzolla, A., Pezzullo, L., Scerrino, G., Spiezia, S., Testini, M., Calo, P. G., Anedda, G., Antonelli, G., Arrigoni, G., Badii, B., Bonati, E., Boniardi, M., Bulfamante, A. M., Candalise, V., Cangiano, A., Canu, G. L., Cappellacci, F., Caracciolo, A., Caruso, E., Casal Ide, E., Chiappini, A., Chiofalo, M. G., Cipolla, C., Costigliola, L., Cozzani, F., Crocco, A., Crocetti, D., De Manzini, N., DI Gioia, A., DI Resta, V., Eramo, R., Erdas, E., Ferriolo, S., Filardo, M., Filograna Pignatelli, M., Gervasi, R., Giudici, F., Gordini, L., Gurrado, A., Impellizzeri, H., Inama, M., Koleva Radica, M., Laforgia, R., Lattarulo, S., Loderer, T., Lucchini, R., Mascioli, F., Marcellinaro, R., Menditto, R., Melfa, G., Minuto, M., Misso, C., Offi, C., Orlando, G., Ossola, P., Pagetta, C., Pasculli, A., Patrone, R., Pauna, I., Pennetti Pennella, F., Pietrasanta, D., Pino, A., Pinto, V. L., Piras, S., Polistena, A., Portinari, M., Reina, S., Rotolo, G., Russo, G., Scalise, E., Sgaramella, L. I., Sibilla, M. G., Spinelli, S., Spoletini, D., Curto, L. S., Tascone, M., Torresan, F., Varaldo, E., Viviani, E., and Zucca, A.

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, AcademicSubjects/MED00910, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), pandemics, NO, Pandemic, Research Letter, medicine, humans, Thyroid cancer, Thyroid Neoplasm, LS7_4, Thyroid Neoplasms, Thyroidectomy, SARS-CoV-2, COVID-19, Pandemics, Italy, business.industry, thyroid neoplasms, Retrospective cohort study, medicine.disease, Comorbidity, comorbidity, retrospective studies, thyroidectomy, Settore MED/18 - Chirurgia Generale, Emergency medicine, Surgery, AcademicSubjects/MED00010, business
Abstract

N/A

Published
2021

39. The THYCOVIT (Thyroid Surgery during COVID-19 pandemic in Italy) study: results from a nationwide, multicentric, case-controlled study

Author

Medas, F., Ansaldo, G. L., Avenia, N., Basili, G., Boniardi, M., Bononi, M., Bove, A., Carcoforo, P., Casaril, A., Cavallaro, G., Chiofalo, M. G., Conzo, G., De Pasquale, L., Del Rio, P., Dionigi, G., Dobrinja, C., Docimo, G., Graceffa, G., Iacobone, M., Innaro, N., Lombardi, C. P., Palestini, N., Pedicini, F., Perigli, G., Pezzolla, A., Scerrino, G., Spiezia, S., Testini, M., Calo, P. G., Anedda, G., Antonelli, G., Arrigoni, G., Badii, B., Bonati, E., Bulfamante, A. M., Candalise, V., Cangiano, A., Canu, G. L., Cappellacci, F., Caracciolo, A., Caruso, E., Annamaria, D. A., Ide, E. C., Chiappini, A., Cipolla, C., Costigliola, L., Cozzani, F., Crocco, A., Crocetti, D., Demanzini, N., Digioia, A., Diresta, V., Eramo, R., Erdas, E., Ferriolo, S., Filardo, M., Filograna Pignatelli, M., Gervasi, R., Giudici, F., Gordini, L., Gurrado, A., Impellizzeri, H., Inama, M., Koleva Radica, M., Laforgia, R., Lattarulo, S., Loderer, T., Lucchini, R., Mascioli, F., Marcellinaro, R., Menditto, R., Melfa, G., Minuto, M., Misso, C., Offi, C., Orlando, G., Ossola, P., Pagetta, C., Pasculli, A., Patrone, R., Pauna, I., Pennetti Pennella, F., Pietrasanta, D., Pino, A., Pinto, V. L., Piras, S., Polistena, A., Portinari, M., Reina, S., Rotolo, G., Russo, G., Scalise, E., Sgaramella, L. I., Sibilla, M. G., Spinelli, S., Spoletini, D., Curto, L. S., Tascone, M., Torresan, F., Varaldo, E., Viviani, E., Zucca, A., Medas, Fabio, Ansaldo, Gian Luca, Avenia, Nicola, Basili, Giancarlo, Boniardi, Marco, Bononi, Marco, Bove, Aldo, Carcoforo, Paolo, Casaril, Andrea, Cavallaro, Giuseppe, Chiofalo, Maria Grazia, Conzo, Giovanni, De Pasquale, Loredana, Del Rio, Paolo, Dionigi, Gianlorenzo, Dobrinja, Chiara, Docimo, Giovanni, Graceffa, Giuseppa, Iacobone, Maurizio, Innaro, Nadia, Lombardi, Celestino Pio, Palestini, Nicola, Pedicini, Francesco, Perigli, Giuliano, Pezzolla, Angela, Scerrino, Gregorio, Spiezia, Stefano, Testini, Mario, Calò, Pietro Giorgio, Calogero, Cipolla, Medas, F., Ansaldo, G. L., Avenia, N., Basili, G., Boniardi, M., Bononi, M., Bove, A., Carcoforo, P., Casaril, A., Cavallaro, G., Chiofalo, M. G., Conzo, G., De Pasquale, L., Del Rio, P., Dionigi, G., Dobrinja, C., Docimo, G., Graceffa, G., Iacobone, M., Innaro, N., Lombardi, C. P., Palestini, N., Pedicini, F., Perigli, G., Pezzolla, A., Scerrino, G., Spiezia, S., Testini, M., Calo, P. G., Anedda, G., Antonelli, G., Arrigoni, G., Badii, B., Bonati, E., Bulfamante, A. M., Candalise, V., Cangiano, A., Canu, G. L., Cappellacci, F., Caracciolo, A., Caruso, E., Annamaria, D. A., Ide, E. C., Chiappini, A., Cipolla, C., Costigliola, L., Cozzani, F., Crocco, A., Crocetti, D., Demanzini, N., Digioia, A., Diresta, V., Eramo, R., Erdas, E., Ferriolo, S., Filardo, M., Filograna Pignatelli, M., Gervasi, R., Giudici, F., Gordini, L., Gurrado, A., Impellizzeri, H., Inama, M., Koleva Radica, M., Laforgia, R., Lattarulo, S., Loderer, T., Lucchini, R., Mascioli, F., Marcellinaro, R., Menditto, R., Melfa, G., Minuto, M., Misso, C., Offi, C., Orlando, G., Ossola, P., Pagetta, C., Pasculli, A., Patrone, R., Pauna, I., Pennetti Pennella, F., Pietrasanta, D., Pino, A., Pinto, V. L., Piras, S., Polistena, A., Portinari, M., Reina, S., Rotolo, G., Russo, G., Scalise, E., Sgaramella, L. I., Sibilla, M. G., Spinelli, S., Spoletini, D., Curto, L. S., Tascone, M., Torresan, F., Varaldo, E., Viviani, E., and Zucca, A.

Subjects
COVID-19, Endocrine surgery, SARS-CoV-2, Thyroid carcinoma, Thyroidectomy, medicine.medical_specialty, medicine.medical_treatment, Thyroid Gland, Humans, Italy, Retrospective Studies, Pandemics, NO, Retrospective Studie, Pandemic, Epidemiology, medicine, Thyroid cancer, LS7_4, business.industry, Thyroid disease, Case-control study, Retrospective cohort study, medicine.disease, Surgery, Original Article, business, Human
Abstract

The outbreak of the COVID-19 pandemic has led to a disruption of surgical care. The aim of this multi-centric, retrospective study was to evaluate the impact of the pandemic on surgical activity for thyroid disease among the Italian Units of Endocrine Surgery. Three phases of the pandemic were identified based on the epidemiological situation and the public measures adopted from the Italian Government (1st phase: from 9th March to 3rd May 2020; 2nd phase: from 4th May to 14th June; 3rd phase: from 15th June to 31st). The patients operated upon during these phases were compared to those who underwent surgery during the same period of the previous year. Overall, 3892 patients from 28 Italian endocrine surgical units were included in the study, 1478 (38%) operated upon during COVID-19 pandemic, and 2414 (62%) during the corresponding period of 2019. The decrease in the number of operations was by 64.8%, 44.7% and 5.1% during the three phases of COVID-19 pandemic, compared to 2019, respectively. During the first and the second phases, the surgical activity was dedicated mainly to oncological patients. No differences in post-operative complications were noted between the two periods. Oncological activity for thyroid cancer was adequately maintained during the COVID-19 pandemic.

Published
2021

43. Molecular profiles of malignant colorectal polyps within the European Polyp Surveillance Study (EPOS IV).

Author

Korcz, W., Mroz, A., Szmit, M., Nilsen, J. A., Antonelli, G., Bretthauer, M., Krzyżkowiak, J., Orzeszko, Z., Spychalski, P., Kobiela, J., Pilonis, N. D., and Kaminski, M. F.

Subjects
COLON polyps, ADENOMATOUS polyps, POLYPS, TUMOR-infiltrating immune cells
Abstract

This article, published in the journal Endoscopy, discusses a study conducted to assess the risk of recurrence and metastasis in patients with pT1 colorectal cancer (CRC) who underwent endoscopic or surgical treatment. The study analyzed various histological biomarkers, including conventional ones such as grade of differentiation and lymphovascular invasion, as well as novel ones like desmoplastic response and tumor infiltrating lymphocytes. The analysis included 75 patients, and after a median follow-up time of 3.7 years, 10.6% of patients experienced recurrence or metastases. The study identified two novel biomarkers that, when combined with conventional ones, could optimize endoscopic treatment of T1 CRC. [Extracted from the article]

Published
2024
Full Text
View/download PDF

46. Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group

Author

Svicher, V., Alteri, C., Montano, M., Nori, A., D’Arrigo, R., Andreoni, M., Angarano, G., Antinori, A., Antonelli, G., Allice, T., Bagnarelli, P., Baldanti, F., Bertoli, A., Borderi, M., Boeri, E., Bon, I., Bruzzone, B., Barresi, R., Calderisi, S., Callegaro, A. P., Capobianchi, M. R., Gargiulo, F., Castelli, F., Cauda, R., Ceccherini-Silberstein, F., Clementi, M., Chirianni, A., Colafigli, M., D’Arminio Monforte, A., De Luca, A., Di Biagio, A., Di Nicuolo, G., Di Perri, G., Di Santo, F., Fadda, G., Galli, M., Gennari, W., Ghisetti, V., Costantini, A., Gori, A., Gulminetti, R., Leoncini, F., Maffongelli, G., Maggiolo, F., Maserati, R., Mazzotta, F., Meini, G., Micheli, V., Monno, L., Mussini, C., Nozza, S., Paolucci, S., Palù, G., Parisi, S., Parruti, G., Pignataro, A. R., Quirino, T., Re, M. C., Rizzardini, G., Sanguinetti, M., Santangelo, R., Scaggiante, R., Sterrantino, G., Turriziani, O., Vatteroni, M. L., Viscoli, C., Vullo, V., Zazzi, M., Lazzarin, A., and Perno, C. F.

Published
2014
Full Text
View/download PDF

49. Antibiotic resistance and therapy for H. pylori infection in immigrant patients managed in Italy

Author

Fiorini G, Saracino IM., Zullo A, Pavoni M., Saccomanno L., Lazzarotto T., Cavallo R., Antonelli G., Vaira D., and Fiorini G, Saracino IM., Zullo A, Pavoni M., Saccomanno L., Lazzarotto T., Cavallo R., Antonelli G., Vaira D.

Subjects
resistance, therapy, Helicobacter pylori, immigrant
Abstract

Background: Helicobacter pylori (H. pylori) infection is the leading cause of both peptic ulcers and gastric tumors, including low-grade MALT-lymphoma and adenocarcinoma. Although it is decreasing in developed countries, H. pylori prevalence remains high in developing areas, mainly due to low socio-economic levels, and the potential consumption of contaminated water. Moreover, a dierent pattern of primary antibiotic resistance is expected in their H. pylori isolates, potentially aecting the ecacy of standard eradication therapies. Indeed, a previous study showed the eradication rate following triple therapy was distinctly lower in dyspeptic H. pylori infected immigrants living in Italy as compared to Italian patients. Aims: to evaluate the resistance pattern in H. pylori isolates from immigrant patients in Italy, and the success rate of first-line therapy in these patients. Materials and Methods: This retrospective study evaluated data of consecutive immigrant patients, diagnosed with H. pylori infection in a single center (Bologna, Italy) between January 2009 and January 2019. Patients underwent first-line therapy with either sequential or Pylera® (Allergan USA, Inc. Madison, NJ, USA) therapy. Results: A total of 609 immigrants were diagnosed with H. pylori infection during the study period, but 264 previously received an eradication therapy. Therefore, the study was focused on 294 out of 345 naïve patients with a successful bacterial culture with antibiogram. Latin America immigrants had the highest overall resistance rate. Levofloxacin resistance rate was significantly higher in Latin Americans and Asians as compared with Europeans. Based on resistance patterns, sequential therapy showed a clear decreasing trend in eradication rates. Conclusions: while antibiotic resistance rates are generally increasing worldwide, Pylera® seems to achieve a good performance as first-line treatment in all naïve foreigner patients, except for Africans.

Published
2020

50. Interferon-β 1a inhibits SARS-CoV-2 in vitro when administered after virus infection

Author

Clementi N., Ferrarese R., Criscuolo E., Diotti R. A., Castelli M., Scagnolari C., Burioni R., Antonelli G., Clementi M., Mancini N., CRISCUOLO , ELENA, Clementi, N., Ferrarese, R., Criscuolo, E., Diotti, R. A., Castelli, M., Scagnolari, C., Burioni, R., Antonelli, G., Clementi, M., Mancini, N., and Criscuolo, Elena

Subjects
SARS-CoV-2, COVID-19 clinical trial, IFN-β 1a
Abstract

The ongoing COVID-19 pandemic has forced the clinical and scientific community to try drug repurposing of existing antiviral agents as a quick option against SARS-CoV-2. Under this scenario, the interferon-β 1a (IFN-β 1a) whose antiviral potential is already known, and is a drug currently used in the clinical management of multiple sclerosis, may represent as a potential candidate. In this report, we demonstrate that IFN-β 1a was highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically achievable concentration when administered after virus infection.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results